Not a candidate for curative surgery or radiation
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB14707 | Cemiplimab | A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. |
| DB15627 | Dostarlimab | An anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers and solid tumours with no alternative treatment options. |
| DB09078 | Lenvatinib | A receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma. |
| DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| DB08828 | Vismodegib | A hedgehog pathway inhibitor used to treat patients with locally advanced or metastatic basal cell carcinoma. |
| Drug | Drug Name | Phase | Status | Count |
|---|